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Although high-dose methotrexate (HD-MTX) is the most effective drug against primary CNS lymphomas (PCNSL), outcome-
determining variables related to its administration schedule have not been defined. The impact on toxicity and outcome of the area
under the curve (AUCMTX), dose intensity (DIMTX) and infusion rate (IRMTX) of MTX and plasmatic creatinine clearance (CLcrea) was
investigated in a retrospective series of 45 PCNSL patients treated with three different HD-MTX-based combinations.
Anticonvulsants were administered in 31 pts (69%). Age 460 years, anticonvulsant therapy, slow IRMTX (p800mgm
 2h
 1), and
reduced DIMTX (p1000mgm
 2wk
 1) were significantly correlated with low AUCMTX values. Seven patients (16%) experienced
severe toxicity, which was independently associated with slow CLcrea. A total of 18 (40%) patients achieved complete remission after
chemotherapy, which was independently associated with slow CLcrea. In all, 22 patients were alive at a median follow-up of 31
months, with a 3-year OS of 4079%; slow CLcrea and AUCMTX 41100mmolhl
 1 were independently associated with a better
survival. Slow CLcrea and high AUCMTX are favourable outcome-determining factors in PCNSL, while slow CLcrea is significantly
related to higher toxicity. AUCMTX significantly correlates with age, anticonvulsant therapy, IRMTX, and DIMTX. These findings, which
seem to support the choice of an MTX dose X3gm
 2 in a 4–6-h infusion, every 3–4 weeks, deserve to be assessed prospectively
in future trials. MTX dose adjustments in patients with fast CLcrea should be investigated.
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High-dose methotrexate (HD-MTX) is the most effective drug
against primary central nervous system lymphomas (PCNSL)
(Reni et al, 1997; Ferreri et al, 2002b). Any chemotherapy regimen
without HD-MTX is associated with outcomes no better than those
obtained with radiotherapy (RT) alone in these malignancies
(Schultz et al, 1996; O’Neill et al, 1999; Mead et al, 2000), while the
survival benefit of the addition of other drugs to HD-MTX remains
a matter of debate (Reni et al, 2001; Ferreri et al, 2002b). In spite of
its central role in PCNSL treatment, the optimal dose, adminis-
tration schedule, and dose timing of MTX have not been clearly
defined. Moreover, contrary to what is observed in other
malignancies in which MTX plays a crucial role, such as acute
leukaemia (Evans et al, 1986) and osteosarcoma (Graf et al, 1994;
Delepine et al, 1995; Bacci et al, 1998), where a significant
association between MTX parameters and outcome has been
reported, the impact on toxicity and outcome of MTX adminis-
tration schedule has not been investigated in PCNSL.
The analysis of some MTX parameters, such as the area under
the curve (AUCMTX), dose, dose intensity (DIMTX), and infusion
rate (IRMTX), as well as the plasmatic creatinine clearance (CLcrea)
could allow us to identify subgroups of patients with increased risk
of severe toxicity or disappointing outcome, as well as to define the
optimal MTX administration schedule against PCNSL. This paper
reports the analysis of the impact on toxicity and outcome of the
above-mentioned variables in a retrospective multicentre series of
45 immunocompetent patients with PCNSL treated with HD-MTX-
based primary chemotherapy.
PATIENTS AND METHODS
Study population
A questionnaire requesting epidemiological, clinical, histopatho-
logical, therapeutic, and survival data of immunocompetent
patients with PCNSL treated with primary chemotherapy contain-
ing HD-MTX (X1gm
 2), followed or not followed by RT, was sent
to the seven participating centres. In particular, the questionnaire
included body weight and body surface area, creatinine clearance,
theoretical and really administrated dose of MTX, duration of
infusion, timing dose, and MTX serum levels at 0, 24, 48, and 72h.
The use of anticonvulsants, type and dose, was also analysed Revised 1 October 2003; accepted 13 October 2003
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lconsidering the capacity of some of these drugs to interfere with
MTX metabolism (Jacobs et al, 1976). This study conformed to the
tenets of the Declaration of Helsinki and all the patients
accessioned provided signed informed consent to the treatment.
This consent extended to the use of biological, histopathological,
radiological, biochemical, and clinical data for scientific purposes.
MTX variables
CLcrea value, determined before the start of chemotherapy, was
obtained by the formula of Cockcroft and Gault (1976):
CLcreaðmlmin 1Þ¼
ð140   ageÞ bodyweight
creatinineserumlevel 72
CLcrea value in females was considered as 85% of the value for
males.
The MTX variables investigated were AUCMTX, dose, DIMTX,
and IRMTX. The individual AUCMTX (mmolhl
 1) related to the first
course of chemotherapy was determined according to a one-
compartment model by using the statistical population pharma-
cokinetic program P-PHARM-Version 3 (InnaPhase, 77420
Champs-sur-Marne, France), considering MTX dosage and serum
levels at 0, 24, 48, and 72h after drug infusion for calculation.
DIMTX, expressed as mgm
 2wk
 1, was calculated by the Hryniuk
method (Hryniuk and Goodyear, 1990). This was a ratio between
the total dose of MTX administered (mgm
 2) and the treatment
duration expressed in days divided by 7. Treatment duration was
calculated from the first day of the first course to the 22nd or 29th
day of the last course (respectively for regimens administered
every 3 or 4 weeks) (Hryniuk and Goodyear, 1990). The IRMTX,
expressed as mgm
 2h
 1, was defined as the MTX dose (mgm
 2)
administered per hour during the first chemotherapy course.
Statistical considerations
Correlations between AUCMTX and the other variables were
analysed by the Spearman test. The impact of studied variables
on severe toxicity and complete response rate was analysed by
logistic regression. Severe toxicity was defined by the onset of one
of two major events: toxic death or interruption of chemotherapy
due to toxicity. Complete response was defined as the disappear-
ance of all evidence of lymphoma.
CLcrea, AUCMTX,D I MTX, and IRMTX were firstly analysed as
continuous variables; then, quartiles values were applied as cutoff
to differentiate the risk groups (categorical variables): lower
quartile for CLcrea (85mlmin
 1) and upper quartile for DIMTX
(1000mgm
 2wk
 1), for AUCMTX (1100mmolhl
 1), and for IRMTX
(800mgm
 2h
 1).
Survival curves were generated by the Kaplan–Meier method.
The overall survival (OS) was calculated from diagnosis to the date
of death or the last date of follow-up. Impact on survival of clinical
and therapeutic variables was evaluated through the log-rank test.
The independent prognostic value of variables was analysed using
Cox proportional hazard model. All the probability values were
two-sided. All the analyses were carried out using the Statistica 4.0
statistical package for Windows (Statsoft Inc, 1993, Tulsa, OK
74104, USA).
RESULTS
Study group
The study group consisted of 45 patients treated between 1995 and
2001 (Calderoni and Aebi 2002; Pasini et al. 2002; Ferreri et al.
2002a). Patients’ characteristics and extent of disease at diagnosis
are summarised in Table 1. Chemotherapy regimens and MTX
administration schedules are reported in Table 2. All patients were
treated with adequate pre-MTX hydration, urinary alkalinisation,
and escalated leucovorin dosages according to MTX serum levels.
Dehydration, aciduria, renal or cardiac dysfunction, pleural
effusion, or gastrointestinal tract obstruction were excluded before
commencing treatment in all cases. Post-chemotherapy RT, which
Table 1 Patients’ characteristics and extension of disease at diagnosis
Entire series
No. 45
Median age (range) 54 (25–76)
470 years 2 (4%)
Males 29 (64%)
Performance status (ECOG score)
0–1 19 (42%)
2 13 (29%)
3 11 (24%)
4 2 (4%)
Prior cancer
a 2 (4%)
Histotype (REAL/WHO Classification)
Diffuse large B-cell lymphoma 42 (93%)
Anaplastic large-cell Ki1 lymphoma 1 (2%)
Unclassified 2 (4%)
High LDH serum level
b 13/38 (34%)
Intraocular disease
b 1/40 (3%)
Positive CSF cytology examination
b 2/27 (7%)
Elevated CSF protein levels
b,c 13/19 (68%)
Multiple lesions
b 25/45 (56%)
Involvement of deep structures
b,d 25/44 (57%)
CSF¼cerebrospinal fluid.
aPrior cancers: renal cell carcinoma and Waldenstrom’s
macroglobulinaemia.
bRatio between the number of positive cases and the number of
assessed patients.
cThe cutoff to define normal CSF protein levels was 45mgdl
 1 in
patients p60 years and 60mgdl
 1 in patients 460 years.
dDeep structures of the
brain: basal ganglia, corpus callosum, brain stem, and cerebellum. ECOG¼Eastern
Cooperative Oncology Group; LDH¼Lactic Dehydrogenase; REAL¼Reversed
European American lymphoma.
Table 2 Chemotherapy regimens
Regimen
No. of
patients
MTX dose
(mgm
 2)
MTX infusion
(h)
MTX dose
day Other drugs i.t. CHT
Planned no.
of courses
Courses every
weeks
MTX alone 10 1000–3000 4 1 and 7 — Yes/no 2–3 4
(Calderoni and Aebi, 2002) 8000 24
MATILDE 11 3500 3
a 1 AraC 2 gm
 2 2d2 No 3 4
(Ferreri et al, 2002a) IDA 15mgm
 2 d1
TTP 25mgm
 2 d3
MTX+AraC 24 1000–2000
b 24 1 AraC 2 gm
 2 2d2–3 no 3 3
(Pasini et al, 2002)
MTX¼methotrexate; i.t. CHT¼intrathecal chemotherapy; AraC¼cytarabine; IDA¼idarubicin; TTP¼thiotepa.
aInfusion preceded by an initial MTX bolus.
bFour patients
received 3500–8000mgm
 2 in 24-h infusion. DIMTX (mean7s.d.) of the used chemotherapy regimens were 163871642, 8447180, and 78071080mgm
 2week
 1
(P¼0.01), respectively, for HD-MTX alone, MATILDE, and MTX+Ara-C combination.
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lconsisted of whole-brain irradiation, followed or not followed by a
tumour-bed boost, was planned in all cases, but it was in fact
performed as part of the first-line therapy in 31 patients, with
median brain and tumour-bed doses of 3675 and 4279Gy, and as
part of salvage therapy in six cases. Anticonvulsants were
administered in 31 patients (69%), and consisted of phenobarbital
(100–150mgd
 1) in 27 cases, hydantoin (100–300mgd
 1) in two
cases and carbamazepine (400–800mgd
 1) in two cases.
MTX parameters
The mean value7s.d. of CLcrea was 119757mlmin
 1. The mean
value7s.d. of AUCMTX was 7317525mmolhl
 1. Patients p60
years old displayed a faster CLcrea (mean7s.d.: 118738 vs
94728mlmin
 1; P¼0.01), and a higher AUCMTX (8467562 vs
5027359mmolhl
 1; P¼0.02) with respect to patients 460.
According to the PS, patients with an ECOG score of 3–4
displayed a similar CLcrea (100728 vs 112735mlmin
 1; P¼0.17)
and a similar AUCMTX (139771208 vs 12387836mmolhl
 1;
P¼0.53) with respect to patients with a PS of 0–2. The mean
value7s.d. of DIMTX was 99271140mgm
 2week
 1. Seven
patients (16%) received only one course of chemotherapy (severe
toxicity in five, no response in two), 16 (36%) received two, 14
(31%) received three, and eight (18%) received more than three
courses. No difference in the used MTX dose according to age or
PS was observed; the proportion of patients p60 years old and
460 treated with a dose 43gm
 2 was similar (47 vs 47%,
P¼0.99); 53% of patients with PS 0–2 and 31% of patients with PS
3–4 received an MTX dose 43gm
 2 (P¼0.19). No cases of
reduction of more than 25% of the MTX dose in further courses
with respect to the planned dose were observed. The MTX dose of
the further courses was increased by more than 25% with respect
to the MTX dose of the first course in three (7%) cases. The mean
value7s.d. of IRMTX during the first chemotherapy course was
4757423mgm
 2h. This parameter remained unmodified during
further courses in all cases.
AUCMTX-determining variables
Variables significantly correlated with the AUCMTX are reported in
Table 3. Anticonvulsant use and age correlated inversely with
AUCMTX, while a direct correlation between AUCMTX and IRMTX
and DIMTX was observed. No correlation with sex, performance
status (PS), and CLcrea was observed. Patients treated with
MATILde chemotherapy regimen achieved significantly higher
AUCMTX values.
Severe toxicity
The predictive value of MTX variables on severe toxicity was
analysed considering toxic death (n¼2) and interruption of
chemotherapy due to toxicity (n¼5) as events. Severe toxicity
consisted of pulmonary thromboembolism in two cases (lethal in
both), sepsis in two, acute renal failure in one, and persistent grade
IV thrombocytopenia in two. These events were observed during the
first two courses of chemotherapy. As reported in Table 4, CLcrea
was independently associated with severe toxicity; a significantly
higher toxicity rate was observed in patients with a CLcrea
p85mlmin
 1. Importantly, a DIMTX 41000mgm
 2/week, and an
AUCMTX 41100mmolhl
 1 were not related to a higher toxicity.
Objective response
After primary chemotherapy, 18 patients (40%) achieved a
complete remission and 16 (36%) a partial response (overall
response rate¼ 76%); four patients (9%) had stable disease, five
(11%) experienced progressive disease, and two (4%) died of
toxicity. As reported in Table 4, a slow CLcrea (p85mlmin
 1) was
significantly and independently associated with a higher complete
remission rate.
Overall survival
A total of 26 patients experienced failure: early progression of
the disease in nine cases, relapse after initial response (complete
and partial) in 15 and toxic death in two cases, with a 2-year
failure-free survival of 5078%. In all, 22 patients are alive
(19 NED) at a median follow-up of 31 months (range 4–72
months), with a 3-year OS of 4079%. The cause of death was
lymphoma in 20 cases, acute toxicity in two, and unrelated
disorder in one.
Univariate analyses showed that patients with a slow CLcrea
(p85mlmin
 1) survived longer than patients with a fast CLcrea
(485mlmin
 1), with 3-year OS values of 88713 and 2579%
(P¼0.0005), respectively (Figure 1). Patients treated with an
AUCMTX 41100mmolhl
 1 survived significantly longer than
patients treated with lower levels (3-year OS: 78712 vs 3279%;
P¼0.05) (Figure 2). The use of anticonvulsants and IRMTX was not
associated with survival, and no significant difference in the
efficacy of the used chemotherapy regimens was observed.
Multivariate analysis (Table 5) confirmed the independent
prognostic value of CLcrea and AUCMTX.
DISCUSSION
The present study focused on the impact on toxicity and outcomes
of CLcrea, AUCMTX,D I MTX, and IRMTX in a multicentre retro-
spective series of 45 immunocompetent patients with PCNSL. This
series is representative of PCNSL patients currently treated with
HD-MTX-based chemotherapy, since it displays similar median
age, PS distribution, histotypes, and ocular and meningeal
infiltration rates with respect to more comprehensive unselected
Table 3 Correlations between AUCMTX and the other analysed
variables
Variables Subgroups No.
AUCMTX
(mean7s.d.
lmolhl
 1) P
Age p60 years 30 8467562
460 years 15 5027359 0.02
Sex Females 16 5407398
Males 29 8377562 0.08
PS 0–1 19 9277614
2–4 26 5897405 0.08
Anticonvulsants No 14 10287662
Yes 31 5987394 0.04
IRMTX (mgm
 2h
 1) p800 33 6357564
4800 12 9967274 0.003
DIMTX (mgm
 2week
 1) p1000 33 5597392
41000 12 12067567 0.0003
CLcrea (mlmin
 1) p85 12 6047434
485 33 7787553 0.35
Chemotherapy regimen HD-MTX 10 8577658
MATILde 11 10437240
MTX+AraC 24 5367491 0.008
PS¼performance status according to the ECOG score.
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lretrospective series (Ferreri et al, 2002b), and to the largest
published prospective trials (O’Brien et al, 2000; Deangelis et al,
2002). A clear relationship between the studied variables and
therapeutic outcome is difficult to establish, considering the
multitude of other factors, such as protein binding, membrane
transport, dihydrofolate reductase levels, tissue distribution, or
concurrent drugs, which may also influence the efficacy of MTX.
Nevertheless, as has been reported for other malignancies (Evans
et al, 1986; Graf et al, 1994; Delepine et al, 1995; Bacci et al, 1998),
the characterisation of the MTX variables investigated could be
useful to identify different risk groups and to define the optimal
administration schedule of this drug in PCNSL patients.
HD-MTX is the most effective drug against PCNSL; any regimen
without this drug is associated with outcomes which are no better
than with RT alone (Schultz et al, 1996; O’Neill et al, 1999; Mead
et al, 2000). When used as primary treatment, alone or combined
Table 4 Logistic regression: variables correlated to severe toxicity (n¼7) and complete remission rate (n¼18) after primary chemotherapy
Variables Subgroups No. Severe toxicity P Complete response P
Age p60 years 30 3 (10%) 11 (37%)
4 60 years 15 4 (27%) 0.28 7 (46%) 0.26
PS 0–1 16 2 (13%) 10 (62%)
2–4 29 5 (17%) 0.14
a 8 (28%) 0.19
Anticonvulsants No 14 1 (7%) 6 (43%)
Yes 31 6 (19%) 0.97 12 (39%) 0.51
IRMTX (mgm
 2h
 1) p800 33 4 (12%) 15 (45%)
4800 12 3 (33%) 0.11 3 (25%) 0.49
DIMTX (mgm
 2week
 1) p1000 33 6 (18%) 14 (42%)
41000 12 1 (8%) 0.48 4 (33%) 0.52
CLcrea (mlmin
 1) p85 12 4 (33%) 8 (67%)
485 33 3 (9%) 0.05 10 (30%) 0.02
AUCMTX (mmolhl
 1) p1100 34 6 (17%) 14 (41%)
41100 11 1 (9%) 0.45 4 (36%) 0.95
Chemotherapy regimen HD-MTX 10 0 (0%) 2 (20%)
MATILde 11 3 (27%) 3 (27%)
MTX+AraC 24 4 (17%) 0.25 13 (54%) 0.08
HD-MTX¼high-dose methotrexate.
aThe incidence of severe complications was significantly higher in patients with a PS42 with respect to the others (41 vs 9%, P¼0.002). An
additional logit analysis with patients grouped according to PSp2 vs 42 confirmed the independent association between toxicity and CLcrea.
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Figure 1 OS curves for patients grouped according to the CLcrea.
Patients with a slow CLcrea (p85mlmin
 1; dotted line) showed a better
OS with respect to patients with a fast CLcrea (485mlmin
 1; continued
line).
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Figure 2 OS curves for patients grouped according to the AUCMTX.
Patients treated with an AUCMTX 41100mmolh l
 1 (continued line)
showed a significantly better survival with respect to those treated with an
AUCMTX p1100mmolh l
 1 (dotted line).
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lwith other drugs, followed or not followed by RT, HD-MTX
produces a response rate of 70–80%, with a 2-year OS of 60–70%
(Ferreri et al, 2000). The survival benefit of the addition of other
drugs to HD-MTX is matter of debate, considering that not only do
randomised trials comparing mono-chemotherapy with HD-MTX
and poly-chemotherapy not exist, but also that the activity of these
drugs has not been assessed as a single drug in prospective trials.
Thus, HD-MTX remains a crucial drug against PCNSL, being an
irreplaceable component of primary chemotherapy. Nevertheless,
the prognostic role of the AUCMTX and DIMTX as well as the
optimal MTX dose, IR and dose timing of this drug have not been
clearly defined in PCNSL. A single study comparing some MTX
parameters in PCNSL patients treated with blood–brain barrier
disruption or with systemic chemotherapy has been reported
(Zylber-Katz et al, 2000), but their impact on outcome has not
been analysed. Conversely, the prognostic role of MTX pharma-
cokinetics has been reported in other malignancies in which this
drug plays a critical role, such as acute leukaemia (Evans et al,
1986) and osteosarcoma (Graf et al, 1994; Delepine et al, 1995;
Bacci et al, 1998). Patients with acute leukaemia have been
grouped according to a slow, medium or fast CLMTX, obtaining an
inverse association with outcome (Evans et al, 1986). A significant
correlation between a faster CLMTX and lower serum and
cerebrospinal fluid (CSF) MTX concentrations has also been
documented, suggesting an insufficient treatment both of the brain
and meninges, and a greater risk of CNS relapse in this subgroup
of leukaemia patients (Evans et al, 1983). Likewise, a significant
survival effect of serum peak concentration of MTX has been
reported in osteosarcoma (Graf et al, 1994).
Our study suggests that CLcrea and AUCMTX are independent
predictors of MTX efficacy in PCNSL patients also. A CLcrea
p85mlmin
 1 was associated with a higher complete remission
rate and better survival, which was independent of age, PS, DIMTX,
IRMTX, and other therapeutic variables. Patients treated with an
AUCMTX 41100mmolhl
 1 showed a significantly better survival
with respect to those treated with lower AUCMTX levels. CLMTX is
defined based upon CLcrea; decreased CLcrea represents decreased
CLMTX, which for a given dose would produce an increased
AUCMTX. However, in the present series, CLcrea and AUCMTX are
two independent variables, which is explained by the heterogeneity
in MTX dose, DIMTX, and IRMTX, as well as by differences in the
MTX metabolism, according to the drug infusion duration (see
below). A strongly inverse correlation between CLcrea and AUCMTX
could be observed, for example, in a prospective trial, where the
used MTX dose and schedule is the same for the entire series.
Considering that AUCMTX is significantly correlated, among
others, with DIMTX,I R MTX, and anticonvulsant therapy, changes
in these parameters could lead to significant changes in AUCMTX
and efficacy. Importantly, as reported in Table 4, a higher AUCMTX
was not associated with a higher incidence of severe toxicity (9 vs
17%, P¼0.45). The single case of severe toxicity in the group of
patients treated with an AUCMTX 41100mmolhl
 1 consisted of
nonlethal persistent thrombocytopenia, without bleeding compli-
cations in a patient with a CLcrea of 186mlmin
 1. On the other
hand, four of the five cases of severe renal and haematological
toxicity were observed in patients with slow CLcrea. A close follow-
up with haematologic profile and renal function assessment
appears advisable in this subgroup of patients.
Pretreatment CLcrea assessment could also be useful to identify
groups of PCNSL patients with different MTX efficacy, and the use
of higher doses in patients with a fast CLcrea should be critically
considered. The choice of the MTX dose is a relevant issue in
PCNSL, especially because of the high interpatient and intrapatient
variability of MTX pharmacokinetics. For example, in a recently
published trial (Batchelor et al, 2003), the MTX dose (8gm
 2) was
adjusted based on the pre-chemotherapy CLcrea. The dose was
reduced by the percentage decrease of this variable below
100mlmin
 1. The schedule employed was well tolerated; however,
a detailed analysis of the impact on activity and toxicity of this
strategy was not provided. Our data suggest that changes in MTX
dose according to the pretreatment CLcrea could lead to more
suitable AUCMTX levels, with a consequent efficacy improvement.
This interesting hypothesis will be studied in a prospective series
treated with a homogeneous MTX schedule.
DI is a debated outcome-conditioning factor in aggressive
systemic lymphomas, while its role has not been investigated in
PCNSL patients treated with conventional strategies. In the present
series, DIMTX was not associated with survival or toxicity.
However, the significant association between a DIMTX
41000mgm
 2week
 1 and higher AUCMTX levels seems to suggest
that, when administered every 3–4 weeks, a MTX dose
X3000mgm
 2 could produce better results than lower doses.
This also seems to be supported by the MSKCC and RTOG
experience (Deangelis et al, 1992, 2002). In a previous trial
(Deangelis et al, 1992), MTX administered at a dose of 1gm
 2
produced an overall response rate of 64% and a 5-year OS of 28%,
while, in a recently reported trial (Deangelis et al, 2002), the use of
a 3.5-gm
 2 MTX dose produced an overall response rate of 90%
and a 5-year OS of 50%. Analysed together, these data suggest that
a higher amount of MTX administered in a single dose increases
drug exposure and activity. Moreover, as previously reported
(Pitman and Frei, 1977; Evans et al, 1983), this strategy seems to
lead to a higher diffusion of the drug across the blood–brain
barrier and increased drug concentrations in the CSF, with a
potential positive impact on efficacy against PCNSL.
From the present analysis, no significant association between
IRMTX and survival was observed. This could be due to the strong
correlation observed between this parameter and AUCMTX. The
identification of the best IRMTX in PCNSL needs further studies. In
the meantime, an IRMTX of 4800mgm
 2h
 1 appears advisable,
since it is associated with higher AUCMTX and does not display
significantly higher toxicity in comparison to slower rates.
Anticonvulsants are commonly used in PCNSL patients
presenting seizures. These drugs interact with hepatic aldehyde
oxidase, which constitutes a major mechanism for MTX degrada-
tion (Jacobs et al, 1976). Anticonvulsant therapy increases the
systemic CLMTX, as well as the level of other cytostatics, and is
associated with lower efficacy of chemotherapy in children treated
for acute lymphoblastic leukaemia (Relling et al, 2000). This effect
seems to be more intense in patients treated with HD-MTX by a
24-h infusion, in whom about 40% of the drug is metabolised in
the liver, whereas, when HD-MTX is administered as a short
intravenous infusion (4–6h), most of the drug is cleared by the
kidneys (Evans et al, 1983). In the present analysis, no association
between anticonvulsant use and toxicity and outcome was
observed, and the impact of these drugs in patients treated with
a 24-h infusion cannot be analysed, considering that all these
patients received anticonvulsant therapy. The hypothesis that MTX
Table 5 Multivariate analysis: impact on overall survival of studied
variables
Variables Subgroups Odds ratio (CI 95%) P
Age Continuous variable 1.06 (1.01–1.11) 0.04
PS 0–2 3–4 2.55 (1.92–7.02) 0.05
Anticonvulsant No Yes 1.46 (0.28–7.53) 0.65
IRMTX (mgm
 2h
 1) p800 4800 0.51 (0.11–2.49) 0.41
DIMTX (mgm
 2week
 1) p1000 41000 3.38 (0.53–4.98) 0.21
CLcrea (mlmin
 1) p85 485 6.01 (3.04–9.77) 0.005
AUCMTX (mmolhl
 1) p1100 41100 0.11 (0.01–0.77) 0.03
Cytarabine
a No Yes 1.19 (0.34–4.11) 0.78
Alkylating agents
a No yes 4.41 (0.75–5.61) 0.16
aSimilar results were obtained when analysis was performed according to the
chemotherapy regimen.
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porarily used should be better explored.
To identify new active drugs and combinations remains
the most important strategy to improve therapeutic results in
PCNSL patients, and any effort to define the best administration
schedule for HD-MTX should be encouraged. With certain
limitations due to their retrospective nature, our data seem to
suggest that slow CLcrea and high AUCMTX are independently
associated with better outcome in PCNSL patients. Comprehen-
sively, these interesting findings deserve to be assessed in
prospective trials. In the meantime, a MTX dose X3000mgm
 2
administered in a 4- or 6-h infusion, every 3–4 weeks, appears an
advisable schedule to adopt in clinical practice. The need to
increase the MTX dose to ensure adequate exposure, such as
higher AUCMTX values, in patients with a fast CLcrea, should be
critically considered.
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